Karel Petrak

Karel Petrak

New concepts in drug targeting at NangioTx

Joined 03/15/2016


- generated safety, toxicity and efficacy preclinical data, and designed several clinical studies (mucositis, necrotizing enterocolitis, head and neck cancer, severe sepsis) which showed talactoferrin to be effective in Phase 2 clinical studies. - raised $10+ MM federal funds to support the above clinical studies.

- led development of gene-based products for asthma, rheumatoid arthritis, and transplant rejection project funded by Syntex (later Roche) with a total budget of $17 million. I filed patents for the electroporation and ultrasonic-nebulization technologies for gene delivery.

- managed a testing laboratory and a data management/statistics group (staff of 20, monitoring 5000+ studies) and streamlined stability testing to achieve 20% reduction of the overall work-volume and costs.

- developed self-assembling nanoparticles that avoided recognition by the reticulo-endothelial system of the body – a property essential for a systemic delivery of site-specific systems.

- developed and patented new photographic and electro resist materials, a surfactant-specific electrode, and a method for measuring diffusion of oxygen through coated polymer layers. I also developed polymer/polymer interactions and phase separation systems which found a major practical application in the company’s coating technology.

Published over 100 scientific publications and patents.

Specialties: Project leadership and management in all aspects of drug research and development.
Rewards expand_more






Level: LEVEL 03 (12mo pts: 572 pts)

Lifetime points: 1021 pts

Experience expand_more
Chief Scientific Officer at NangioTx
VP for R&D at Agennix Inc.
Director and Program Head at Gene Medicine
VP R&D at GeneRxPlus
Research Area Head at Ciba-Geigy / Novartis
Follow back expand_more

Followed by 0

No followers yet.

Activities expand_more


View More
group 0Follower(s)
Start a Talk
Evolving Role of Real-World Evidence (RWE)
In today’s evolving healthcare environment, pharma companies need authoritative evidence to prove their product delivers superior clinical outcomes and demonstrate its value for the patient, payer, provider, and regulatory stakeholders.

Our goal is to explore the evolving role of Real World Evidence (RWE) so companies can deliver clinically and scientifically meaningful results and provide evidence-based insights to stakeholders.
Next-Generation Oncology Treatments
Understanding the potential for new cancer drug treatments from Oncologists
Future Disruptions in the Sweet & Salty Snacks Market
The US Snacking Market - Specifically how to identify growth consumer segments (with enough clarity to build out new marketing audiences using online tools)
Next-Generation Oncology Treatments
Understanding of potential for new cancer drug from Oncologists
Novel Rheumatoid Arthritis Molecules
Clinical development plans and clinical development opportunities for novel RA (rheumatoid arthritis) molecules
Paid Research Panel on Immuno-Oncology Innovations and Trends
What are the leading trends in immuno-oncology (I-O) drug development in the next 5 - 10 years and what implications does this have for manufacturing, administration, and supply chain, for a leading biopharmaceutical company?
Paid Expert Panel on Small Batch Drug Manufacturing

Add at least 3 tags
Your tags